Cargando…

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9 to reduce LDL-C. Evolocumab exhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasichayanula, Sreeneeranj, Grover, Anita, Emery, Maurice G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999140/ https://www.ncbi.nlm.nih.gov/pubmed/29353350 http://dx.doi.org/10.1007/s40262-017-0620-7

Ejemplares similares

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
por: Lee, Edward, et al.
Publicado: (2019)

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
por: Gibbs, John P., et al.
Publicado: (2016)

Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
por: Kuchimanchi, Mita, et al.
Publicado: (2018)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
por: Gibbs, John P., et al.
Publicado: (2016)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
por: Chan, Dick C., et al.
Publicado: (2018)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development
por: Gibbs, John P., et al.
Publicado: (2017)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
por: Choi, Hye Duck, et al.
Publicado: (2023)

C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
por: Nelson, Adam J., et al.
Publicado: (2020)

Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
por: Gandra, Shravanthi R., et al.
Publicado: (2016)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
por: Zhang, Xiang, et al.
Publicado: (2020)

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
por: Dent, Ricardo, et al.
Publicado: (2016)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study
por: Izkhakov, Elena, et al.
Publicado: (2021)

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
por: Rosenson, Robert S., et al.
Publicado: (2019)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
por: Choi, Joshua, et al.
Publicado: (2017)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
por: Silla, Alessia, et al.
Publicado: (2023)

Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2022)

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies
por: Koren, Michael J., et al.
Publicado: (2020)

A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients
por: Stodtmann, Sven, et al.
Publicado: (2021)

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
por: Leucker, Thorsten M., et al.
Publicado: (2020)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
por: Liu, Chao, et al.
Publicado: (2019)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism
por: Wang, Jinhai, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia
por: Peng, Yanren, et al.
Publicado: (2022)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
por: Kohli, Payal, et al.
Publicado: (2016)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6kkjbpudh5bc0nfffql30rfuo7